SCHEMBL17820037

SCHEMBL17820037

Nc1ccc2c(c1)Oc1cccc(Br)c1C2

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.40
NPC1 O15118 2/20 0.40
LMNA P02545 2/20 0.40
RAB9A P51151 2/20 0.40
MAPT P10636 3/20 0.39
KDM4E B2RXH2 2/20 0.39
ALDH1A1 P00352 2/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
MAPKAPK2 P49137 3/20 0.37
MAOA P21397 1/20 0.36
MAOB P27338 1/20 0.36
HPGD P15428 1/20 0.34
TP53 P04637 1/20 0.33
LCK P06239 2/20 0.32
PARP1 P09874 2/20 0.32
TRPA1 O75762 1/20 0.31
CA1 P00915 1/20 0.31
CA2 P00918 1/20 0.31
CA4 P22748 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17827861 0.81 NPC1 (0.40) SMN1; SMN2NPC1LMNARAB9AMAPT
SCHEMBL27747612 0.80 MAOA (0.59) SMN1; SMN2NPC1LMNARAB9AMEN1
Xanthene SCHEMBL27949817 0.78 MAOA (0.63) SMN1; SMN2NPC1LMNARAB9AMAPKAPK2
SCHEMBL17820428 0.78 MAPT (0.41) SMN1; SMN2NPC1LMNARAB9AMAPT
SCHEMBL719137 0.77 MAPT (0.47) SMN1; SMN2NPC1LMNARAB9AMAPT
SCHEMBL374168 0.76 MAOA (0.65) SMN1; SMN2NPC1LMNARAB9AMAPT
SCHEMBL17820545 0.76 MEN1 (0.43) LMNARAB9AMAPTKDM4EALDH1A1
SCHEMBL17819520 0.75 AHR (0.47) SMN1; SMN2NPC1LMNARAB9AMAPT
SCHEMBL17819791 0.74 NPC1 (0.37) SMN1; SMN2NPC1RAB9AMEN1KMT2A
SCHEMBL10824984 0.68 MAPT (0.43) SMN1; SMN2NPC1LMNARAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3042900-B1 NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF FUJIFILM CORP (JP) 2020-09-23 EP disclosed
US-9586951-B2 Morpholine derivative or salt thereof FUJIFILM CORPORATION (JP) 2017-03-07 US disclosed
US-9586951-B2 Morpholine derivative or salt thereof FUJIFILM CORPORATION (JP) 2017-03-07 US disclosed
EP-3042900-A1 NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF Fujifilm Corporation (JP) 2016-07-13 EP disclosed
US-20160168139-A1 NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF FUJIFILM CORPORATION (JP) 2016-06-16 US disclosed
US-20160168139-A1 NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF FUJIFILM CORPORATION (JP) 2016-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160168139-A1 NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF PRMT7, RBBP7, RER1 SMN1; SMN2 1734/4885NPC1 3926/4885LMNA 2540/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.